January 16, 2004Cardiovascular Research
The endothelin system in pulmonary arterial hypertension
Why the study?
Do endothelin-1 receptor antagonists improve clinical and hemodynamic outcomes in patients with pulmonary arterial hypertension?
Population
Patients with pulmonary arterial hypertension (PAH) and animal models of PAH
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports endothelin antagonism in PAH; leaves open prospective validation and agent comparisons in modern regimens.
Structured PICO
Do endothelin-1 receptor antagonists improve clinical and hemodynamic outcomes in patients with pulmonary arterial hypertension?
P
Population
Patients with pulmonary arterial hypertension (PAH) and animal models of PAH
I
Intervention
Endothelin-1 receptor antagonists (e.g., bosentan, sitaxentan)
Endothelin-1 receptor antagonists effectively antagonize the over-activated ET-1 system in PAH, improving clinical and hemodynamic parameters, though liver enzyme elevation remains a key side effect.
Cite This Study
Nazzareno Galiè (2004) studied this question.